Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
OwnerAnahit GHOCHIKYAN, Michael AGADJANYANinventors
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods of treating tauopathies (e.g. Alzheimer's disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia with Parkinsonism linked to chromosome 17, Pick's Disease, Progressive Supranuclear Palsy, Dementia Pugilistica, Down's Syndrome and others) by administering humanized antibodies. The disclosure also provides the anti-tau humanized antibodies that bind the N-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes).
Claims14
A method of treating tauopathy in an individual, the method comprising administrating to the subject a pharmaceutical composition comprising:
- a. a pharmaceutically acceptable excipient suitable for administration to human and
- b. a humanized anti-tau antibody that comprises:
- (i) a VH CDR1 comprising the amino acid sequence of SEQ ID No:
- 23,
- (ii) a VH CDR2 comprising the amino acid sequence of SEQ ID No:
- 24,
- (iii) a VH CDR3 comprising the amino acid sequence of SEQ ID No:
- 25
- (iv) a VL CDR1 comprising the amino acid sequence of SEQ ID No:
- 26,
- (v) a VL CDR2 comprising the amino acid sequence of SEQ ID No:
- 27,
- (vi) a VL CDR3 comprising the amino acid sequence of SEQ ID No:
- 28,
- (vii) a VH CDR1 comprising the amino acid sequence of SEQ ID No:
- 29,
- (viii) a VH CDR2 comprising the amino acid sequence of SEQ ID No:
- 30,
- (ix) a VH CDR3 comprising the amino acid sequence of SEQ ID No:
- 31,
- (x) a VL CDR1 comprising the amino acid sequence of SEQ ID No:
- 32,
- (xi) a VL CDR2 comprising the amino acid sequence of SEQ ID No:
- 33,
- (xii) a VL CDR3 comprising the amino acid sequence of SEQ ID No:
- 34,
- (xiii) a VH CDR1 comprising the amino acid sequence of SEQ ID No:
- 35,
- (xiv) a VH CDR2 comprising the amino acid sequence of SEQ ID No:
- 36,
- (xv) a VH CDR3 comprising the amino acid sequence of SEQ ID No:
- 37
Dependencies are inferred from the claim text.